Business
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
CULVER CITY, Calif., March 17, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/c32eb6d886834e311e00146c313e54bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ybDtpRK1GYfTBzQRKZrqCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c32eb6d886834e311e00146c313e54bc","width":480,"height":270}},"lazy":false},{"type":"text","content":"Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"CULVER CITY, Calif., March 17, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.","length":517,"tagName":"p"},{"type":"text","content":"This update expands previous NCCN clinical guideline recommendations, which included patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary disease, to now also recognize patients with BCG-unresponsive NMIBC with papillary-only disease as candidates for treatment with ANKTIVA plus BCG. Both recommendations are Category 2A. The immunotherapy regimen is designed to activate natural killer (NK) cells and T cells and has demonstrated durable responses in clinical studies. The NCCN guideline reference to ANKTIVA® for patients with BCG-unresponsive NMIBC with papillary-only disease reflects a use that is not included in the current U.S. Food and Drug Administration approved indication for ANKTIVA.","length":737,"tagName":"p"},{"type":"text","content":""These updated NCCN guideline recommendations in bladder cancer represent an important milestone for patients with BCG-unresponsive NMIBC papillary-only disease who have exhausted standard BCG therapy," said Patrick Soon-Shiong, M.D., F...